Double-blind, randomised, placebo controlled low level laser therapy study in patients with primary Raynaud's phenomenon.

What the authors concluded

Frequency of Raynaud's attacks was not significantly affected by low level laser therapy. Compared to placebo a significantly lower intensity of attacks during laser irradiation was observed, but no transfer effect occurred." Comment: Couldn't retrieve full text, but based on their 2004 study, they might have used an active red LED as the placebo, which would be a methodologically controversial.

Devices that emit this wavelength

Matched on wavelength within 15nm, since LED bins vary by roughly that much and a tighter match would be false precision. Where we have an irradiance figure, the session length is the time needed to reach this study's dose of 2 J/cm² at that intensity.

Matching a wavelength is not the same as reproducing a trial. Session times assume the device's published irradiance is accurate at the distance it was measured, which on brand-claim figures is often optimistic. Where a device publishes both a peak and an average we use the average, and where it publishes a falloff curve we use the lowest figure, so these times run long rather than short. Clinical protocols also control for spot size, contact and skin type in ways a home device cannot.